What is Bios?
BIOS Health is at the forefront of developing AI-powered neural interfaces designed to harness the potential of the nervous system for treating chronic diseases, with an initial focus on cardiac conditions. The company is establishing a new category of digital health treatments that utilize real-time neural data for highly personalized and precise medicine. Their proprietary technology enables the measurement and analysis of neural data, paving the way for the creation of targeted pharmaceuticals and software-delivered therapies. BIOS aims to empower individuals with greater control over their health, thereby enhancing the quality of life for those managing lifelong conditions.
How much funding has Bios raised?
Bios has raised a total of $4.5M across 1 funding round:
Other Financing Round
$4.5M
Other Financing Round (2018): $4.5M with participation from Real Ventures
Key Investors in Bios
Real Ventures
Real Ventures is a venture capital firm established in 2007 that backs visionary founders building innovative tech companies with large-scale positive societal impacts. They provide guidance and stage-specific support to entrepreneurs.
What's next for Bios?
The substantial enterprise-level funding Bios has attracted signals a critical growth phase, likely focused on scaling its AI-driven neural interface technology and expanding its therapeutic applications beyond cardiac conditions. This strategic investment will probably fuel further research and development, clinical trials, and market penetration. The company's vision of creating a new field of digital health treatments positions it for significant impact in precision medicine, potentially attracting further capital as it demonstrates clinical efficacy and commercial traction.
See full Bios company page
